BioMarin Fails to Win Approval for Drug to Treat DuchenneBy
FDA told company it didn't hit `substantial evidence' standard
Stock declines, analyst said investors had expected rejection
BioMarin Pharmaceutical Inc. failed to win U.S. approval for a drug to treat Duchenne muscular dystrophy, a deadly genetic disease that usually affects young boys.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.